BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—
—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.